Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus MALARONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE versus MALARONE.
Hydroxychloroquine vs MALARONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxychloroquine is a 4-aminoquinoline antimalarial agent that accumulates in lysosomes and inhibits Toll-like receptor signaling, reduces cytokine production, and interferes with antigen presentation. It also inhibits heme polymerase in malarial parasites, leading to toxic heme accumulation.
Atovaquone is a selective inhibitor of the mitochondrial electron transport chain at the cytochrome bc1 complex (Complex III), disrupting pyrimidine synthesis and ATP generation in Plasmodium species. Proguanil, via its metabolite cycloguanil, inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. Synergistic activity against erythrocytic and exoerythrocytic stages.
400 mg orally once daily or 200 mg orally twice daily, then 200-400 mg orally once daily for maintenance, depending on indication.
For malaria treatment: 4 tablets (each containing atovaquone 250 mg/proguanil 100 mg) orally once daily for 3 consecutive days. For malaria prophylaxis: 1 tablet (atovaquone 250 mg/proguanil 100 mg) orally once daily starting 1-2 days before travel, continued during travel and for 7 days after leaving endemic area.
None Documented
Clinical Note
moderateHydroxychloroquine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxychloroquine."
Clinical Note
moderateHydroxychloroquine + Artemether
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
Clinical Note
moderateHydroxychloroquine + Chloroquine
"The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
Clinical Note
moderateNone Documented
Terminal half-life: 30-60 days (prolonged due to extensive tissue binding); clinical context: requires loading dose for rapid effect.
Atovaquone: 50-70 hours (mean ~60 h); proguanil: 12-21 hours (mean ~16 h); cycloguanil: 10-16 hours. Long half-life of atovaquone allows single-dose treatment, but may delay parasite clearance.
Primarily renal (30-60% unchanged); minor hepatic metabolism; fecal elimination accounts for ~20-30%.
Atovaquone: 94% excreted unchanged in feces via biliary elimination, 6% in urine. Proguanil: 40-60% excreted unchanged in urine; cycloguanil (active metabolite) and proguanil metabolites also cleared renally.
Category A/B
Category C
Antimalarial / DMARD
Antimalarial
Hydroxychloroquine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."